Literature DB >> 22407977

Characterization of neutralizing affinity-matured human respiratory syncytial virus F binding antibodies in the sub-picomolar affinity range.

Gabriela A Canziani1, Jose A Melero, Eilyn R Lacy.   

Abstract

In the human adaptation and optimization of a mouse anti-human respiratory syncytial virus neutralizing antibody, affinity assessment was crucial to distinguish among potential candidates and to evaluate whether this correlated with function in vitro and in vivo. This affinity assessment was complicated by the trimeric nature of the antigen target, respiratory syncytial virus F (RSV-F) glycoprotein. In the initial affinity screen, surface plasmon resonance was used to determine the intrinsic binding affinities of anti-RSV-F Fab and immunoglobulin G (IgG) to the extracellular domain of RSV-F. This assessment required minimal biotinylation of the RSV-F protein and design of a capture strategy to minimize avidity effects. Approximately 30 Fabs were selected from three optimization phage display libraries on the basis of an initial ELISA screen. Surface plasmon resonance analysis demonstrated the success of optimization with some candidates from the screened libraries having low picomolar dissociation constants, more than 700-fold tighter than the parental monoclonal antibody (B21M). The affinities of these antibodies were further evaluated by a kinetic exclusion assay, a solution binding technology. One IgG (monoclonal antibody 029) displayed a low picomolar K(D) comparable with that of motavizumab, an RSV antibody in clinical study. Kinetic exclusion assay showed that two other of the matured IgGs (011 and 019) had sub-picomolar dissociation constants that could not be resolved further. We discuss the relevance of these interaction analysis results in the light of recently published data on the mechanism of F-driven viral fusion during paramyxoviral infection and 101F epitope conservation revealed from the recent crystal structure of RSV-F in the post-fusion state.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22407977     DOI: 10.1002/jmr.2149

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  5 in total

1.  Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.

Authors:  Kodandaram Pillarisetti; Gordon Powers; Leopoldo Luistro; Alexander Babich; Eric Baldwin; Yingzhe Li; Xiaochun Zhang; Mark Mendonça; Nate Majewski; Rupesh Nanjunda; Diana Chin; Kathryn Packman; Yusri Elsayed; Ricardo Attar; François Gaudet
Journal:  Blood Adv       Date:  2020-09-22

2.  A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.

Authors:  Kodandaram Pillarisetti; Suzanne Edavettal; Mark Mendonça; Yingzhe Li; Mark Tornetta; Alexander Babich; Nate Majewski; Matt Husovsky; Dara Reeves; Eileen Walsh; Diana Chin; Leopoldo Luistro; Jocelin Joseph; Gerald Chu; Kathryn Packman; Shoba Shetty; Yusri Elsayed; Ricardo Attar; François Gaudet
Journal:  Blood       Date:  2020-04-09       Impact factor: 22.113

3.  High throughput solution-based measurement of antibody-antigen affinity and epitope binning.

Authors:  Patricia Estep; Felicia Reid; Claire Nauman; Yuqi Liu; Tingwan Sun; Joanne Sun; Yingda Xu
Journal:  MAbs       Date:  2013 Mar-Apr       Impact factor: 5.857

4.  Kinetic mechanism of controlled Fab-arm exchange for the formation of bispecific immunoglobulin G1 antibodies.

Authors:  Dennis R Goulet; Steven J Orcutt; Adam Zwolak; Theo Rispens; Aran F Labrijn; Rob N de Jong; William M Atkins; Mark L Chiu
Journal:  J Biol Chem       Date:  2017-11-17       Impact factor: 5.157

5.  Characterization of a Novel Bispecific Antibody That Activates T Cells In Vitro and Slows Tumor Growth In Vivo.

Authors:  Olesya Chornoguz; Catherine N Leettola; Karen Leander; Kerry Brosnan; Eva Emmell; Mark L Chiu; Sandra Santulli-Marotto
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2019-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.